The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MOF Pitching 2-Step Drug Price Tweaks in 2019 Tax Hike Year
May 25, 2018
-
ORGANIZATION Isao Teshirogi Elected New FPMAJ Chairman
May 25, 2018
-
REGULATORY PMDA, FDA Team Up to Help Developing Countries to Facilitate Pediatric Drug Development
May 24, 2018
-
BUSINESS Astellas Eyes 1 Trillion Yen Peak Sales with 6 Late-Stage Assets: Biz Plan
May 23, 2018
-
BUSINESS Hemlibra, MSD/Astellas’ DPP-4/SGLT2 Combo Hit Japan Market
May 23, 2018
-
BUSINESS Kyowa Kirin to Use Surrogate Endpoint in PIII Trial of Sakigake CKD Treatment; Application Could Come as Early as 2022
May 22, 2018
-
TRENDS Daiichi Sankyo Espha Sales Double as It Cashes In On Authorized Generic Boom
May 21, 2018
-
BUSINESS 10 Major Japan Drug Makers’ Sales Up 3.3%, but Decline Expected for FY2018 on Price Revision
May 18, 2018
-
REGULATORY Chuikyo Rep Frowns on Low Manufacturing Cost Disclosure, Says New Rule Might Need Revisiting
May 17, 2018
-
REGULATORY Pricing OK’ed for Hemlibra, Parmodia; Prevymis 1st in 3 Years to Get At-Launch Premium for Innovation
May 17, 2018
-
BUSINESS Eisai Chalks Up 1st Double-Digit Growth in 11 Years on Merck Deal, Global Brands
May 16, 2018
-
BUSINESS Velcade Sales Would Slide 50%, but Weber Stresses Takeda’s Strong Momentum
May 15, 2018
-
BUSINESS Latuda Use Patent Suit Could Wrap Up in December: Sumitomo Dainippon Chief
May 14, 2018
-
BUSINESS Sumitomo Dainippon’s Sales Hike 14.3% Buoyed by Latuda
May 14, 2018
-
BUSINESS Ono to Boost Oncology Reps to Prep for Opdivo Label Expansions
May 11, 2018
-
BUSINESS Takeda Confident It Can Reduce Debt Quickly after Shire Takeover: CEO
May 11, 2018
-
BUSINESS Mitsubishi Tanabe Logs Record Sales, but Profits Sag on Higher R&D/SGA Costs
May 10, 2018
-
BUSINESS Pfizer Japan Cedes Crown as Top Rep Holder as Global Players Continue to Seek Leaner Sales Force: Survey
May 9, 2018
-
BUSINESS Takeda Attracted to Shire’s High Profitability, Rare Disease Pipeline: CEO
May 9, 2018
-
BUSINESS Takeda Cuts Deal to Acquire Shire in Japan’s Biggest Buyout
May 8, 2018
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…